Mitomycin

Chemical formula: C₁₅H₁₈N₄O₅  Molecular mass: 334.327 g/mol  PubChem compound: 5746

Therapeutic indications

Mitomycin is indicated for:

Advanced metastatic gastric carcinoma

Population group: only adults (18 years old or older)

Mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of advanced metastatic gastric carcinoma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced and/or metastatic breast cancer

Population group: only adults (18 years old or older)

Mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of advanced and/or metastatic breast cancer.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell bronchial carcinoma

Population group: only adults (18 years old or older)

Non-small cell lung cancer

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Advanced pancreatic carcinoma

Population group: only adults (18 years old or older)

Carcinoma of pancreas

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Superficial urinary bladder carcinoma

Population group: only elderly (65 years old or older)

Intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Mitomycin is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Cystitis

Cystitis

Perforation of the bladder wall

Carcinoma of urinary bladder, invasive

Acute infections

Infectious disease

Haemorrhagic diathesis

Blood coagulation disorder

Pancytopenia

Pancytopenia

Leucopoenia

Leukopenia

Thrombopenia

Thrombocytopenic disorder

Restrictive or obstructive disturbances to pulmonary ventilation, renal dysfunction, liver dysfunction, radiotherapy

at least one of
Lung function restrictive
Decreased respiratory function
Obstructive ventilatory defect
Renal failure
Hepatic insufficiency
† Radiation oncology AND/OR radiotherapy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: MITOMYCIN Powder for solution for injection or infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈